Analytical Data
-
基因名
SSSCA1
- Application
-
别名
ZNRD2;SSSCA1;Protein ZNRD2
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O60232
-
表达区间
1-199aa
-
氨基酸序列
MGSSHHHHHHSSGLVPRGSHMGSMALNGAEVDDFSWEPPTEAETKVLQAR RERQDRISRLMGDYLLRGYRMLGETCADCGTILLQDKQRKIYCVACQELD SDVDKDNPALNAQAALSQAREHQLASASELPLGSRPAPQPPVPRPEHCEG AAAGLKAAQGPPAPAVPPNTDVMACTQTALLQKLTWASAELGSSTSLETS IQLCGLIRACAEALRSLQQLQH
-
分子量
24 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The SSSCA1 (Slow Skeletal Muscle and Cardiac Isoform 1) protein has gained attention in the field of biomedical research due to its significant role in muscle physiology and potential implications in various muscular disorders. Initially identified in studies focusing on skeletal muscle function, SSSCA1 is believed to be involved in the regulation of muscle contraction and energy metabolism. Abnormalities in SSSCA1 expression have been associated with muscular dystrophies and other myopathies, highlighting its potential as a biomarker for muscle-related diseases. The increasing prevalence of such conditions necessitates a deeper understanding of the molecular mechanisms involving SSSCA1, which can pave the way for novel therapeutic strategies. Recent advancements in recombinant protein technology have enabled researchers to produce SSSCA1 in heterologous systems, facilitating in-depth studies of its structure and function. These studies aim to elucidate the protein's interaction with other muscle proteins, its post-translational modifications, and its role in muscle development and regeneration. Ultimately, characterizing SSSCA1 through recombinant protein research holds promise for advancing our knowledge of muscle biology and developing targeted interventions for muscular disorders.
